Baseline severity of depression predicts antidepressant drug response relative to escitalopram
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The intent of this pooled analysis was to determine the relationship between baseline depression symptom severity and treatment response for escitalopram compared to that for other pooled antidepressant medications (citalopram, duloxetine, fluoxetine, paroxetine, sertraline and venlafaxine). METHODS: Data were pooled from controlled clinical trials comparing escitalopram with other antidepressants for the treatment of major depression. The 15 trials meeting the inclusion criteria comprised 2,216 patients treated with escitalopram and 2,085 treated with one of the other antidepressants. The primary outcome measure of change from baseline to week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score was analyzed by an analysis of covariance, using the method of last-observation-carried-forward for missing values and adjusting for baseline and center values. RESULTS: There was a significant interaction between baseline MADRS total score and treatment group (p = 0.0208). Response to escitalopram was stable regardless of baseline severity. For the pooled active comparators, response decreased with increasing baseline symptom severity. This differential efficacy of escitalopram with increasing symptom severity was confirmed by the analyses of the pooled 24-item Hamilton Depression Rating Scale (HAMD-24) results. A HAMD-24 single item analysis indicated that the sum of the baseline psychomotor retardation and hopelessness item scores significantly predicted which patients would benefit from treatment with escitalopram versus a comparator. CONCLUSION: Newer generation antidepressant medications clearly differ in their efficacy as a function of baseline symptom severity. The selective serotonin reuptake inhibitor escitalopram had superior efficacy in the treatment of more severe depression, perhaps attributable to differential efficacy related to symptoms of negativistic thinking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341 · cited 1×
“Improvement in hypothalamic–pituitary–adrenal (HPA) function associated with repeated dexamethasone/corticotropin releasing hormone (DEX/CRH) testing significantly predicted antidepressant treatment response in individuals with severe depression [8].”
BackgroundLepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168 · cited 1×
“2 [42] PC.”
Executive Dysfunction, Heart Disease Burden, and Remission of Geriatric Depression
Alexopoulos, G. S., Kiosses, D. N., Murphy, C., & Heo, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300557 · Cited by 117
Baldwin, D. S., Cooper, J. A., Huusom, A. K. T., & Hindmarch, I. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194377.88330.1d · Cited by 100
Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression
Shelton, R. C., Andorn, A. C., Mallinckrodt, C. H., Wohlreich, M. M., Raskin, J., Watkin, J. G., & Detke, M. J. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32821c6189 · Cited by 39 · cited 1×
“Whereas escitalopram has demonstrated superior efficacy to duloxetine in severe depression [32], and to venlafaxine on some efficacy outcomes [33], it may thus share with the dual serotonin and norepinephrine reuptake inhibitors venlafaxine [9,15] and duloxetine [34] the ability to maintain antidepressant efficacy wit…”
Background
Cited by
The severity of psychiatric disorders
Zimmerman, M., Morgan, T. A., & Stanton, K. (2018) · World Psychiatry · doi:10.1002/wps.20569 · Cited by 227
Wagner, S., Engel, A., Engelmann, J., Herzog, D., Dreimüller, N., Müller, M. B., Tadić, A., & Lieb, K. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.07.003 · Cited by 73
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Comparative efficacy of escitalopram in the treatment of major depressive disorder
Lam, R., & Ali (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12531 · Cited by 33
“The results are consistent with evidence from pooled analyses that the comparative effect sizes in favor of escitalopram increase with increasing baseline severity.(16,24,25) They are also consistent with those from head-to-head randomized controlled trials that prospectively enrolled patients with severe depression.”
ResultEfficacy and safety of escitalopram in treatment of severe depression in Chinese population
Si, T., Wang, G., Yang, F., Fang, Y., Fang, M., Li, J., Dong, J., Shen, X., Zhuo, J., Rui, Q., et al. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-9992-5 · Cited by 20
“…analysis, it is reported that the baseline severity of some MADRS items score such as negative thinking, apparent sadness and reported sadness, inner tension and pessimistic thoughts predict a great benefit effect of escitalopram treatment compared to other active comparators (Kilts et al. 2009).”
BackgroundResultInfluential
Metadata
- Authors
- Kilts, C. D., Wade, A. G., Andersen, H. F., & Schlaepfer, T. E.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2009-03-24
- Volume
- 10
- Issue
- 6
- Pages
- 927-936
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1975727668
- Cited by
- 58
- References
- 7
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.